Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IP-Cure-B proof-of-concept trial of selgantolimod with nucleos(t)ide analogue discontinuation in chronic hepatitis B
2024-515739-32-00Phase 2Completed
- Sponsor
- ANRS
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of selgantolimod in Chronic Hepatitis B (CHB), sponsored by ANRS. Primary endpoint: HBsAg decline of at least 1.0 log10 IU/mL at week 76. Started Jan 2022; status: completed.
02
Drugs
selgantolimod
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on 2024-515739-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515739-32-00.